August 19, 2017 8:30 PM ET

Biotechnology

Company Overview of OncoMed Pharmaceuticals, Inc.

Company Overview

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The company’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 rec...

800 Chesapeake Drive

Redwood City, CA 94063

United States

Founded in 2004

122 Employees

Phone:

650-995-8200

Fax:

650-298-8600

Key Executives for OncoMed Pharmaceuticals, Inc.

Chairman, Chief Executive Officer and President
Age: 57
Total Annual Compensation: $535.1K
Executive Vice President of Research and Development
Age: 65
Total Annual Compensation: $407.6K
Compensation as of Fiscal Year 2016.

OncoMed Pharmaceuticals, Inc. Key Developments

OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2017

OncoMed Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported total revenue of $6,195,000 compared to $6,665,000 a year ago.  Net loss was $15,225,000 or $0.40 per basic and diluted share compared to $27,691,000 or $0.91 per basic and diluted share a year ago. Loss from operations was $15,435,000 against $27,816,000 for the same period a year ago. Loss before income taxes was $15,221,000 against $27,687,000 for the same period a year ago. The decrease in revenue was primarily due to slightly lower revenue recognized from reimbursement of research and development costs for services performed in the second quarter of 2017. The change in net loss from the prior year quarter was due to lower R&D and G&A expenses and restructuring charges. For the six months, the company reported total revenue of $12,408,000 compared to $13,015,000 a year ago.  Net loss was $37,833,000 or $1.01 per basic and diluted share compared to $54,902,000 or $1.81 per basic and diluted share a year ago. Loss from operations was $38,193,000 against $55,062,000 for the same period a year ago. Loss before income taxes was $37,825,000 against $54,896,000 for the same period a year ago.

OncoMed Pharmaceuticals, Inc. to Report Q2, 2017 Results on Aug 02, 2017

OncoMed Pharmaceuticals, Inc. announced that they will report Q2, 2017 results at 9:02 PM, GMT Standard Time on Aug 02, 2017

OncoMed Pharmaceuticals, Inc., Q2 2017 Earnings Call, Aug 02, 2017

OncoMed Pharmaceuticals, Inc., Q2 2017 Earnings Call, Aug 02, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OncoMed Pharmaceuticals, Inc., please visit www.oncomed.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.